Alector, Inc.ALECEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for neurodegenerative diseases. Its product pipeline targets unmet medical needs including Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease, and it collaborates with global pharmaceutical partners to advance candidate therapies through clinical trials.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| FMR LLC | 15.00% | 12.6M | ▲ +0.48pp | 2024-02-09 |
| NOS. OF ABOVE PERSONS | 9.90% | 9.7M | — | 2024-12-06 |
| BlackRock, Inc. | 9.60% | 8.1M | — | 2024-01-24 |
| The Vanguard Group | 5.21% | 4.4M | — | 2024-02-13 |
| Polaris Venture Partners VI, L.P. | 0.50% | 498.5K | flat | 2024-11-12 |
Insider Transactions
Net 90d: −$278.6K · buys $0 / sells $278.6KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-16 | Wong-Sarad Grace | Principal Accounting Officer | Sell (open market) | 1.8K | $2.65 | $4.8K |
| 2026-03-15 | Berkley Neil Lindsay | CFO & Chief Business Officer | Grant | 54.6K | $0.00 | $0 |
| 2026-03-13 | Arnon Rosenthal | Chief Executive Officer | Grant | 116.2K | $0.00 | $0 |
| 2026-03-10 | Wong-Sarad Grace | Principal Accounting Officer | Sell (open market) | 1.0K | $2.65 | $2.6K |
| 2026-03-03 | Wong-Sarad Grace | Principal Accounting Officer | Sell (open market) | 3.4K | $2.08 | $7.0K |
| 2026-03-02 | Wong-Sarad Grace | Principal Accounting Officer | Sell (open market) | 8.1K | $2.12 | $17.1K |
| 2026-03-02 | Arnon Rosenthal | Chief Executive Officer | Sell (open market) | 81.9K | $2.12 | $173.8K |
| 2026-03-02 | Berkley Neil Lindsay | CFO & Chief Business Officer | Sell (open market) | 29.6K | $2.12 | $63.0K |
| 2026-02-26 | Wong-Sarad Grace | Principal Accounting Officer | Sell (open market) | 4.1K | $2.50 | $10.2K |
1–9 of 9